Targeted Chemotherapy for Brain Metastases
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases (CP1005B016)
Metastases to the brain is difficult to treat because the vast majority of drugs are not able to cross the blood-brain barrier. GRN1005 is an investigational chemotherapy drug that was designed to take advantage of a natural mechanism that allows essential substances, like hormones and lipids, to enter the brain. It works by linking the standard chemotherapy drug paclitaxel (TaxolŽ) to a protein "key" that helps substances to cross the blood-brain barrier. The goal of this trial is to determine the safety and effectiveness of GRN1005 when it is given to individuals who have breast cancer that has spread to the brain.
This is a Phase II trial